Rockefeller Capital Management L.P. Reduces Stock Position in Merit Medical Systems, Inc. $MMSI

Rockefeller Capital Management L.P. lessened its holdings in Merit Medical Systems, Inc. (NASDAQ:MMSI) by 22.6% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 435,587 shares of the medical instruments supplier’s stock after selling 127,051 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in Merit Medical Systems were worth $38,393,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of MMSI. Tudor Investment Corp ET AL bought a new position in shares of Merit Medical Systems in the third quarter worth about $2,913,050,000. SG Americas Securities LLC bought a new stake in Merit Medical Systems during the 4th quarter valued at about $1,537,000. Bessemer Group Inc. lifted its holdings in Merit Medical Systems by 54.2% during the 4th quarter. Bessemer Group Inc. now owns 313,981 shares of the medical instruments supplier’s stock valued at $27,674,000 after buying an additional 110,392 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Merit Medical Systems by 7.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 917,122 shares of the medical instruments supplier’s stock valued at $76,332,000 after buying an additional 64,920 shares during the period. Finally, William Blair Investment Management LLC boosted its position in Merit Medical Systems by 16.8% in the 3rd quarter. William Blair Investment Management LLC now owns 863,996 shares of the medical instruments supplier’s stock valued at $71,910,000 after buying an additional 124,396 shares during the period. Hedge funds and other institutional investors own 99.66% of the company’s stock.

Merit Medical Systems Price Performance

MMSI opened at $67.22 on Monday. The business’s 50-day moving average is $65.45 and its two-hundred day moving average is $74.63. Merit Medical Systems, Inc. has a 1 year low of $59.74 and a 1 year high of $96.74. The company has a debt-to-equity ratio of 0.45, a current ratio of 5.08 and a quick ratio of 3.46. The firm has a market capitalization of $4.01 billion, a PE ratio of 29.10, a price-to-earnings-growth ratio of 2.09 and a beta of 0.54.

Merit Medical Systems (NASDAQ:MMSI) last released its quarterly earnings results on Thursday, April 30th. The medical instruments supplier reported $0.94 EPS for the quarter, beating the consensus estimate of $0.84 by $0.10. Merit Medical Systems had a net margin of 9.03% and a return on equity of 13.54%. The business had revenue of $381.88 million during the quarter, compared to analyst estimates of $377.59 million. During the same period in the prior year, the firm posted $0.86 earnings per share. The company’s quarterly revenue was up 7.4% on a year-over-year basis. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. Research analysts anticipate that Merit Medical Systems, Inc. will post 3.62 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Robert W. Baird set a $83.00 target price on shares of Merit Medical Systems in a research report on Friday, May 1st. Wall Street Zen lowered Merit Medical Systems from a “strong-buy” rating to a “buy” rating in a report on Sunday, April 5th. Canaccord Genuity Group dropped their price objective on Merit Medical Systems from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Needham & Company LLC reduced their price objective on Merit Medical Systems from $101.00 to $90.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Finally, Weiss Ratings cut Merit Medical Systems from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, May 8th. Eight investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $92.80.

Insider Activity at Merit Medical Systems

In other Merit Medical Systems news, Director Lynne N. Ward sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $62.61, for a total value of $313,050.00. Following the completion of the sale, the director directly owned 7,809 shares in the company, valued at $488,921.49. This trade represents a 39.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Brian G. Lloyd purchased 2,000 shares of the business’s stock in a transaction on Thursday, May 7th. The stock was purchased at an average cost of $62.62 per share, for a total transaction of $125,240.00. Following the completion of the acquisition, the insider directly owned 2,000 shares of the company’s stock, valued at approximately $125,240. The trade was a ? increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 0.70% of the company’s stock.

Merit Medical Systems Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.